Cargando…

Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction

INTRODUCTION: Hidradenitis suppurativa (HS) has been linked to higher cardiovascular risk (CVR) due to its inflammatory burden. There is little evidence on how biologic treatment could modify the cardiovascular risk of patients with HS. The aims of the present study were to explore the modification...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Díaz, Manuel, Salvador-Rodríguez, Luis, Cuenca-Barrales, Carlos, Arias-Santiago, Salvador, Molina-Leyva, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984601/
https://www.ncbi.nlm.nih.gov/pubmed/36787042
http://dx.doi.org/10.1007/s13555-023-00898-z
_version_ 1784900775609106432
author Sánchez-Díaz, Manuel
Salvador-Rodríguez, Luis
Cuenca-Barrales, Carlos
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
author_facet Sánchez-Díaz, Manuel
Salvador-Rodríguez, Luis
Cuenca-Barrales, Carlos
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
author_sort Sánchez-Díaz, Manuel
collection PubMed
description INTRODUCTION: Hidradenitis suppurativa (HS) has been linked to higher cardiovascular risk (CVR) due to its inflammatory burden. There is little evidence on how biologic treatment could modify the cardiovascular risk of patients with HS. The aims of the present study were to explore the modification of CVR in patients under adalimumab treatment and to explore the potential factors associated with CVR improvement. METHODS: A prospective longitudinal study was performed. A cohort of patients with HS treated with adalimumab was followed up. Carotid intima–media thickness (IMT) and other clinical and biochemical CVR factors were collected at baseline and 32 weeks after starting the treatment. RESULTS: Twenty-seven patients with severe HS were included. Overall, there were no differences in IMT between baseline (633 μm) and 32 weeks follow-up (634 μm). However, 40.7% (11/27) of the patients presented an improvement in IMT. This group (IMT responders) had a higher prevalence of dyslipidemia, diabetes mellitus, higher HbA1c levels, consumed more tobacco, and had higher BMI at baseline. Moreover, these patients had lower IHS4 scores at baseline and tended to have a greater IMT basal value, indicating a higher burden of subclinical atherosclerosis. CONCLUSIONS: Adalimumab treatment might benefit a subset of patients with HS in terms of cardiovascular risk reduction. In light of the results of the present study patients with classical cardiovascular risk factors, and those with higher burden of subclinical atherosclerosis and with less inflammatory load, may be more likely to improve their IMT during adalimumab treatment.
format Online
Article
Text
id pubmed-9984601
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-99846012023-03-05 Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction Sánchez-Díaz, Manuel Salvador-Rodríguez, Luis Cuenca-Barrales, Carlos Arias-Santiago, Salvador Molina-Leyva, Alejandro Dermatol Ther (Heidelb) Original Research INTRODUCTION: Hidradenitis suppurativa (HS) has been linked to higher cardiovascular risk (CVR) due to its inflammatory burden. There is little evidence on how biologic treatment could modify the cardiovascular risk of patients with HS. The aims of the present study were to explore the modification of CVR in patients under adalimumab treatment and to explore the potential factors associated with CVR improvement. METHODS: A prospective longitudinal study was performed. A cohort of patients with HS treated with adalimumab was followed up. Carotid intima–media thickness (IMT) and other clinical and biochemical CVR factors were collected at baseline and 32 weeks after starting the treatment. RESULTS: Twenty-seven patients with severe HS were included. Overall, there were no differences in IMT between baseline (633 μm) and 32 weeks follow-up (634 μm). However, 40.7% (11/27) of the patients presented an improvement in IMT. This group (IMT responders) had a higher prevalence of dyslipidemia, diabetes mellitus, higher HbA1c levels, consumed more tobacco, and had higher BMI at baseline. Moreover, these patients had lower IHS4 scores at baseline and tended to have a greater IMT basal value, indicating a higher burden of subclinical atherosclerosis. CONCLUSIONS: Adalimumab treatment might benefit a subset of patients with HS in terms of cardiovascular risk reduction. In light of the results of the present study patients with classical cardiovascular risk factors, and those with higher burden of subclinical atherosclerosis and with less inflammatory load, may be more likely to improve their IMT during adalimumab treatment. Springer Healthcare 2023-02-14 /pmc/articles/PMC9984601/ /pubmed/36787042 http://dx.doi.org/10.1007/s13555-023-00898-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Sánchez-Díaz, Manuel
Salvador-Rodríguez, Luis
Cuenca-Barrales, Carlos
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title_full Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title_fullStr Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title_full_unstemmed Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title_short Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
title_sort potential predictors of cardiovascular risk improvement in patients with hidradenitis suppurativa treated with adalimumab: a pivotal study of factors associated with carotid intima–media thickness reduction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984601/
https://www.ncbi.nlm.nih.gov/pubmed/36787042
http://dx.doi.org/10.1007/s13555-023-00898-z
work_keys_str_mv AT sanchezdiazmanuel potentialpredictorsofcardiovascularriskimprovementinpatientswithhidradenitissuppurativatreatedwithadalimumabapivotalstudyoffactorsassociatedwithcarotidintimamediathicknessreduction
AT salvadorrodriguezluis potentialpredictorsofcardiovascularriskimprovementinpatientswithhidradenitissuppurativatreatedwithadalimumabapivotalstudyoffactorsassociatedwithcarotidintimamediathicknessreduction
AT cuencabarralescarlos potentialpredictorsofcardiovascularriskimprovementinpatientswithhidradenitissuppurativatreatedwithadalimumabapivotalstudyoffactorsassociatedwithcarotidintimamediathicknessreduction
AT ariassantiagosalvador potentialpredictorsofcardiovascularriskimprovementinpatientswithhidradenitissuppurativatreatedwithadalimumabapivotalstudyoffactorsassociatedwithcarotidintimamediathicknessreduction
AT molinaleyvaalejandro potentialpredictorsofcardiovascularriskimprovementinpatientswithhidradenitissuppurativatreatedwithadalimumabapivotalstudyoffactorsassociatedwithcarotidintimamediathicknessreduction